KalVista Pharmaceuticals (KALV) Earnings Date, Estimates & Call Transcripts $13.17 -0.71 (-5.12%) Closing price 04:00 PM EasternExtended Trading$13.14 -0.03 (-0.23%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KalVista Pharmaceuticals Earnings Summary KalVista Pharmaceuticals issued Q1 2026 earnings on September 11, 2025, reporting an EPS of -$1.12, which missed analysts' consensus estimates of -$0.91 by $0.21. Quarterly revenue was reported to be $1.43 million, below analysts' expectations of $1.97 million. With a trailing EPS of -$3.94, KalVista Pharmaceuticals' earnings are expected to grow next year, from ($3.56) to ($2.90) per share. Upcoming Q2 Earnings DateDec. 4Before Market OpensEstimatedConsensus EPS (Sep. 11) -$0.91 Actual EPS (Sep. 11) -$1.12 Missed By -$0.21 Actual Revenue (Sep. 11) $1.43MQ1 2026 Earnings ResourcesQ1 2026 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)KALV Upcoming EarningsKalVista Pharmaceuticals' next earnings date is estimated for Thursday, December 4, 2025, based on past reporting schedules. Powered by Get KalVista Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on KalVista Pharmaceuticals and other key companies, straight to your inbox. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Estimated and Actual Earnings DataKALV Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter. KalVista Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20252-$0.90-$0.72-$0.81Q2 20252-$0.91-$0.71-$0.81Q3 20252-$0.89$0.81-$0.04Q4 20252-$0.77-$0.35-$0.56 FY 2025 8 -$3.47 -$0.97 -$2.22 Q1 20261-$0.72-$0.72-$0.72Q2 20261-$0.60-$0.60-$0.60Q3 20261-$0.54-$0.54-$0.54Q4 20261-$0.42-$0.42-$0.42 KalVista Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 12/4/2025(Estimated)--------9/11/2025Q1 2026-$0.91-$1.12 -$0.21-$1.12$1.97M$1.43M7/10/2025Q4 2025-$0.83-$3.69 -$2.86-$0.99$4.20M-12/5/2024Q2 2025-$0.92-$0.91+$0.01-$0.91--9/5/2024Q1 2025-$0.91-$0.87+$0.04-$0.87--7/11/2024Q4 2024-$0.73-$1.02 -$0.29-$1.02--3/11/2024Q3 2024-$0.75-$0.84 -$0.09-$0.84--12/7/2023Q2 2024-$0.76-$0.80 -$0.04-$0.80-- KalVista Pharmaceuticals Earnings - Frequently Asked Questions When is KalVista Pharmaceuticals' earnings date? KalVista Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, December 4th, 2025 based off last year's report dates. Learn more on KALV's earnings history. Did KalVista Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, KalVista Pharmaceuticals (NASDAQ:KALV) missed the analysts' consensus estimate of ($0.91) by $0.21 with a reported earnings per share (EPS) of ($1.12). Learn more on analysts' earnings estimate vs. KALV's actual earnings. How can I listen to KalVista Pharmaceuticals' earnings conference call? The conference call for KalVista Pharmaceuticals' latest earnings report can be listened to online. Listen to Conference Call How can I read KalVista Pharmaceuticals' conference call transcript? The conference call transcript for KalVista Pharmaceuticals' latest earnings report can be read online. Read Transcript How much profit does KalVista Pharmaceuticals generate each year? KalVista Pharmaceuticals (NASDAQ:KALV) has a recorded net income of -$183.44 million. KALV has generated -$3.94 earnings per share over the last four quarters. What is KalVista Pharmaceuticals' EPS forecast for next year? KalVista Pharmaceuticals' earnings are expected to grow from ($3.56) per share to ($2.90) per share in the next year. More Earnings Resources from MarketBeat Related Companies IMVT Earnings Results XENE Earnings Results VKTX Earnings Results OGN Earnings Results KNSA Earnings Results NAMS Earnings Results BHC Earnings Results CGON Earnings Results MLYS Earnings Results IBRX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Wall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a Winner This page (NASDAQ:KALV) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts